Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM1 for Preventing Paclitaxel-Associated Neuropathy
NCT05751668Phase 2Active, not recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Nov 2023
- Primary completion
- Nov 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of monosialotetrahexosylganglioside in chemotherapy-induced peripheral neuropathy (CIPN), sponsored by Cancer and Leukemia Group B. Started Nov 2023; status: active, not recruiting.
02
Drugs
monosialotetrahexosylganglioside
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT05751668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05751668.